Enzyme Inhibitors with Broad Therapeutic Applications

Published by: BCC Research

Published: Jun. 1, 2006 - 191 Pages

Table of Contents

INTRODUCTION

OBJECTIVES AND GOALS OF THE STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE AND FORMAT

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS

BCC ONLINE SERVICES

DISCLAIMER

EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL FORECAST OF ENZYME INHIBITOR CLASS REVENUES, THROUGH 2011 ($ MILLIONS)

SUMMARY FIGURE PERCENTAGE OF REVENUES BY ENZYME INHIBITOR CLASS, IN 2005 AND 2011 (%)

OVERVIEW

BACKGROUND

ENZYMES

FIGURE 1 HOW AN ENZYME COMBINES TWO CHEMICALS

THE FUNCTION OF ENZYME INHIBITORS

TYPES OF INHIBITORS

Competitive, Noncompetitive, and Uncompetitive

FIGURE 2 COMPETITIVE INHIBITION

FIGURE 3 NONCOMPETITIVE INHIBITION

Reversible and Irreversible

Selective and Nonselective

CLASSES OF ENZYME INHIBITORS

TABLE 1 ENZYME INHIBITORS BY CLASS: DEFINITION AND EXAMPLES

CYCLOOXYGENASE INHIBITORS

DNA POLYMERASE INHIBITORS

INTEGRASE INHIBITORS

HIV INTEGRASE

PHOSPHODIESTERASE INHIBITORS

PROTEASE INHIBITORS

HIV PROTEASE

PROTON PUMP INHIBITORS (ATPASE INHIBITORS)

TRANSCRIPTASE INHIBITORS

HIV REVERSE TRANSCRIPTASE

PRODUCTS

COX-2 INHIBITORS

COX-2 PRODUCTS ON THE MARKET

Celebrex

Mobic

The Market for COX-2 Inhibitors

TABLE 2 GLOBAL MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

TABLE 3 US MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

PRODUCTS AWAITING FDA APPROVAL

NEXT-GENERATION COX-2 INHIBITORS

AFTER-EFFECTS OF THE WITHDRAWAL OF VIO

BEXTRA

Creating an Unwarranted Market?

The FDA Takes a Hard Look at Direct-To-Consumer Advertising

The Future of COX-2 Inhibitors

The Effect of Insurance Company Reimbursement

PHOSPHODIESTERASE INHIBITORS

PDE1 INHIBITORS

PDE3 INHIBITORS

PDE3 Inhibitors in Phase II or Later Development

PDE4 INHIBITORS

The Market for PDE4 Inhibitors

TABLE 4 GLOBAL MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

TABLE 5 US MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

PDE4 Inhibitors in Phase II or Later Development

TABLE 6 PDE4 INHIBITORS IN PHASE II OR LATER DEVELOPMENT

Ariflo

Awd12-281

Daxas

IC485

Ono-6126

Drawbacks of PDE4 Inhibitors Currently in Development

PDE5 INHIBITORS

Marketed Products

Cialis

Levitra

Revatio

Viagra

Zydena

The Market for PDE5 Inhibitors

TABLE 7 GLOBAL MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

TABLE 8 US MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

PDE5 Inhibitors in Phase II or Later Development

TABLE 9 PDE5 INHIBITORS IN PHASE II OR LATER DEVELOPMENT

NM 702

TA-1790

Tadalafil

PDE7 INHIBITORS

PDE10 INHIBITORS

PROTON PUMP INHIBITORS

ACIPHEX/PARIET

NE

PREVACID

PRILOSEC/LOSEC

PANTOZOL

PROTONIX/ PROTIUM

TAKEPRON

ZEGERID

GENERIC PROTON PUMP INHIBITORS

COMPARISON OF PROTON PUMP INHIBITORS

TABLE 10 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS

COST OF PROTON PUMP INHIBITORS

THE MARKET FOR PROTON PUMP INHIBITORS

TABLE 11 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

TABLE 12 US MARKET FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

PRODUCT

TRANSCRIPTASE INHIBITORS

LACK OF INCENTIVE TO DEVELOP DRUGS TO TREAT HIV AND AIDS

THE IMPACT OF THE AVAILABILITY OF ANTIRETROVIRAL THERAPY

THE INTRODUCTION OF HAART

TABLE 13 NUMBER OF DEATHS FROM AIDS IN THE US, 1988-2005

THE FIRST GENERIC HIV/AIDS DRUG ENTERS THE US MARKET

EFFORTS TO REDUCE THE COST OF HIV DRUGS IN THE DEVELOPING WORLD

Boehringer Ingelheim and GlaxoSmithKline Sign Agreements

AIDS Healthcare Foundation Lawsuit

Sub-Saharan Africa Generic Production Agreement

Merck Reduces the Cost of Stocrin

EFFORTS TO MAKE GENERIC HIV DRUGS AVAILABLE IN DEVELOPING COUNTRIES

The World Trade Organization Steps In

Generic AIDS Drug Combinations Approved by the FDA for Emergency AIDS Relief Plan

A Strategy to Gain a Foothold in the World Market

Clinton Foundation Negotiates Lower Drug Prices for Poor Countries

Other Struggles to Gain Access to Generic HIV Drugs

“THE 3 BY 5 INITIATIVE”

Main Plan Objectives

Status at the End of 2005

DRUG RESISTANCE IN HIV/AIDS

Definition of Antiviral Drug Resistance

How Resistance Develops

Locations of Mutations

Types of Resistance

Current Status of Resistance

2003 CATCH Study

Resistance among HIV Cases in Europe

TABLE 14 RESISTANCE AMONG HIV-POSITIVE PATIENTS IN EUROPE AS DETERMINED BY THE CATCH STUDY

Conclusions

Novel Drug Resistance Treatment Strategies

Acute Infection and Early Disease Research Program

Types of Drug Resistance Testing

Genotypic and Phenotypic Testing

Genotypic Testing

TABLE 15 PROTEASE MUTATIONS

TABLE 16 REVERSE TRANSCRIPTASE MUTATIONS

Phenotypic Testing

Comparison of Genotypic Versus Phenotypic Testing

TABLE 17 ADVANTAGES AND DISADVANTAGES OF GENOTYPIC VERSUS PHENOTYPIC TESTING

Reimbursement for HIV Drug Resistance Testing

Guidelines for HIV Drug Resistance Testing

The Special Case of Protease Inhibitors

The Rationale for Genotypic Testing for HIV-I Drug Resistance

Available HIV Drug Resistance Tests

SALIVA TESTS APPROVED TO DETECT HIV

COST OF HIV/AIDS TREATMENT

TABLE 18 ESTIMATED ANNUAL COSTS FOR HAART IN US AND SUB-SAHARAN AFRICA

ABBOTT INCREASES THE COST OF NORVIR FIVE-FOLD

TABLE 19 COMPARISON OF AVERAGE ANNUAL COST OF BOOSTED* PROTEASE INHIBITOR-BASED HIV TREATMENT REGIMENS BEFORE AND AFTER NORVIR PRICE INCREASE ($)

AVAILABLE PRODUCTS FOR THE TREATMENT OF HIV INFECTION AND AIDS

TABLE 20 FDA-APPROVED DRUGS FOR THE TREATMENT OF HIV INFECTION/AIDS

THE MARKET FOR ENZYME-INHIBITING PRODUCTS TO TREAT HIV INFECTION AND AIDS

TABLE 21 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS THERAPEUTICS, THROUGH 2011 ($ MILLIONS)

TABLE 22 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS THERAPEUTICS BY PRODUCT, THROUGH 2011 ($ MILLIONS)

FIGURE 4 MARKET SHARE OF ENZYME-INHIBITING HIV/AIDS DRUGS BY PRODUCT CATEGORY, WORLDWIDE SALES: AND 2011 (%)

THE US MARKET FOR ENZYME-INHIBITING HIV/AIDS DRUGS

TABLE 23 US MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS THERAPEUTICS, THROUGH 2011 ($ MILLIONS)

FIGURE 5 US MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS THERAPEUTICS, 2004-2011 ($ MILLIONS)

COMBINATION PRODUCTS EMERGE AS PREFERRED TREATMENT

LEADING MARKETERS OF HIV/AIDS DRUGS

Leaders in the Nucleoside Reverse Transcriptase Inhibitor Class

CATEGORIES OF ENZYME-INHIBITING DRUGS AVAILABLE FOR THE TREATMENT OF HIV/AIDS

Nonnucleoside Reverse Transcriptase Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Nucleotide Reverse Transcriptase Inhibitors

Protease Inhibitors

Side Effects of Marketed HIV Drugs

Adverse Cardiovascular Events

SELECTED TRANSCRIPTASE-INHIBITING DRUGS INTRODUCED TO THE US MARKET IN 2003, 2004 AND 2005

TABLE 24 ENZYME INHIBITING PRODUCT INTRODUCTIONS FOR THE TREATMENT OF HIV INFECTION, US, 2002-2005

Nonnucleoside Reverse Transcriptase Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Emtriva

Epizicom

Truvada

Nucleotide Reverse Transcriptase Inhibitors

Protease Inhibitors

Aptivus

Le

Reyataz

DOSING AND COMPLIANCE CHALLENGES

TABLE 25 DAILY DOSAGE REQUIREMENTS FOR SELECTED HIV/AIDS THERAPIES

TABLE 26 RELATIONSHIP BETWEEN COMPLIANCE AND DOSING FREQUENCY

THE IDEAL TREATMENT REGIMEN

THE NUMBER OF SALVAGE PATIENTS CONTINUES TO INCREASE

ENZYME-INHIBITING DRUGS IN DEVELOPMENT FOR THE TREATMENT AND/OR PREVENTION OF HIV INFECTION AND AIDS

TABLE 27 ENZYME-INHIBITING PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT AND/OR PREVENTION OF HIV INFECTION/AIDS

THE THREE MAIN ENZYME TARGETS FOR ANTIRETROVIRAL DRUGS

Integrase

JTK-303

MK-0518

Protease

Protease Inhibitors in Phase II or Later Development

Brecanavir

Darunavir

Reverse Transcriptase

Nonnucleoside Reverse Transcriptase Inhibitors In Phase II Or Later Development

Calanolide A

Capravirine

Etravirine

MIV-150

MIV-210

TMC-278

Nucleoside Reverse Transcriptase Inhibitors In Phase II Or Later Development

Alovudine

Amdoxovir

Dexelvucitabine

Elvucitabine

Racivir

SPD754

TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF OTHER VIRAL DISEASES

Marketed Transcriptase Inhibitors For The Treatment Of Other Viral Diseases

TABLE 28 MARKETED NUCLEOSIDE ANALOG INHIBITORS FOR THE TREATMENT OF OTHER VIRAL DISEASES

Nucleoside Analogs Introduced Between 2003 and 2006 for the Treatment of Other Viral Diseases

Baraclude

The Market for Nucleoside Analogs to Treat Other Viral Diseases

TABLE 29 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO TREAT OTHER VIRAL DISEASES, THROUGH 2011 ($ MILLIONS)

FIGURE 6 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO TREAT OTHER VIRAL DISEASES, 2004-2011 ($ MILLIONS)

Nucleoside Analogs in Phase II Or Later Development for Other Viral Diseases

Hepatitis B Virus Infection

Clevudine

Elvucitabine

MIV-210

Pradefovir Mesylate

Telbivudine

Tenofovir Disopro

Valtorcitabine

Hepatitis C Virus Infection

GS1392

JTK-003

Valopicitabine

Viramidine

VX-950

Herpesvirus Infections

Valomaciclovir

APPLICATIONS

ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

ASTHMA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

THE ROLE OF CYTOKINES IN ASTHMA AND COPD

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT ASTHMA AND COPD

TABLE 30 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT ASTHMA AND COPD, THROUGH 2011 ($ MILLIONS)

FIGURE 7 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT ASTHMA AND COPD, 2004-2011 ($ MILLIONS)

BENIGN PROSTATIC HYPERPLASIA

CARDIOVASCULAR DISEASES

CONGESTIVE HEART FAILURE

HYPERTENSION

INTERMITTENT CLAUDICATION

PULMONARY ARTERIAL HYPERTENSION

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT CARDIOVASCULAR DISEASES

TABLE 31 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT CARDIOVASCULAR DISEASES, THROUGH 2011 ($ MILLIONS)

FIGURE 8 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT CARDIOVASCULAR DISEASES, 2004-2011 ($ MILLIONS)

ERECTILE DYSFUNCTION

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT ERECTILE DYSFUNCTION

TABLE 32 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT ERECTILE DYSFUNCTION, THROUGH 2011 ($ MILLIONS)

FIGURE 9 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT ERECTILE DYSFUNCTION, 2004-2011 ($ MILLIONS)

GASTROINTESTINAL DISEASES

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT GASTROINTESTINAL DISORDERS

TABLE 33 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT GASTROINTESTINAL DISORDERS, THROUGH 2011 ($ MILLIONS)

FIGURE 10 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT GASTROINTESTINAL DISORDERS, 2004-2011 ($ MILLIONS)

HEPATITIS B VIRUS INFECTION

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS B INFECTION

TABLE 34 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS B INFECTION, THROUGH 2011 ($ MILLIONS)

FIGURE 11 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS B INFECTION, 2004- 2011 ($ MILLIONS)

HEPATITIS C VIRUS INFECTION

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS C INFECTION

TABLE 35 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS C INFECTION, THROUGH 2011 ($ MILLIONS)

HERPESVIRUS INFECTIONS

CYTOMEGALOVIRUS

HERPES SIMPLEX VIRUS

HERPES ZOSTER VIRUS

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HERPESVIRUS INFECTIONS

TABLE 36 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HERPESVIRUS INFECTIONS, THROUGH 2011 ($ MILLIONS)

HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND ACQUIRED IMMUNE DEFICIENCY SYNDROME

HIV AND AIDS STATISTICS

Number of HIV/Living with AIDS Cases in 2005 by Geographic Region

TABLE 37 ESTIMATED NUMBER OF PERSONS INFECTED WITH HIV/LIVING WITH AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION, 2005

Geographic Region 2005 Percentage of Global HIV Cases by Geographic Region

TABLE 38 PERCENTAGE OF GLOBAL HIV CASES BY GEOGRAPHIC REGION, 2005

New HIV Cases in 2005 by Region

TABLE 39 ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION, 2005

2005 AIDS Deaths by Region

TABLE 40 ESTIMATED NUMBER OF DEATHS FROM AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION, 2005

Estimated Number of HIV Cases by Country in 2002 and 2010

TABLE 41 ESTIMATED NUMBER OF PEOPLE INFECTED WITH HIV IN SELECTED COUNTRIES, 2002 AND 2010 (MILLION)

HIV INFECTION AND AIDS CASES IN THE US

THE NEED FOR BETTER ACCESS TO TREATMENT

TABLE 42 PERCENT OF PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT FOR HIV INFECTION BY GEOGRAPHIC REGION

ENZYME INHIBITORS TO TREAT HIV/AIDS

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HIV INFECTION AND AIDS

TABLE 43 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HIV INFECTION AND AIDS, THROUGH 2011 ($ MILLIONS)

FIGURE 12 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HIV INFECTION AND AIDS, 2004- 2011 ($ MILLIONS)

RHEUMATOID ARTHRITIS AND RELATED INFLAMMATORY DISEASES

THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT RHEUMATOID ARTHRITIS AND RELATED

TABLE 44 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING DRUGS TO TREAT RHEUMATOID ARTHRITIS AND RELATED INFLAMMATORY DISEASES, THROUGH 2011 ($ MILLIONS)

COMPANY PROFILES

ABBOTT LABORATORIES

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

ACHILLION PHARMACEUTICALS, INC

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

ALTANA PHARMA

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

BRISTOL-MYERS SQUIBB

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

CELGENE CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

FINANCIAL INFORMATION

CORPORATE STRATEGY

GILEAD SCIENCES INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 45 GILEAD’S PRODUCT PIPELINE

CORPORATE STRATEGY

GLAXOSMITHKLINE PLC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 46 GLAXOSMITHKLINE’S ENZYME INHIBITOR PRODUCT PIPELINE

CORPORATE STRATEGY

ICOS CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

IDENIX PHARMACEUTICALS, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

INCYTE CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 47 INCYTE’S PRODUCT PIPELINE

CORPORATE STRAGEGY

MEDIVIR AB

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 48 MEDIVIR’S PRODUCT PIPELINE

CORPORATE STRATEGY

NOVARTIS AG

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

PFIZER CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

PHARMASSET, INC

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

PLE

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

SANTARUS, INC

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

TIBOTEC PHARMACEUTICALS LTD

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

VALEANT PHARMACEUTICALS INTERNATIONAL

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

Abstract

• During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
• Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
• Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.

• The major current and emerging therapeutic markets for enzyme inhibitors used in human therapeutics,
• A discussion of the biochemistry for enzyme inhibitors and classes of enzyme inhibiting products with broad current or potential therapeutic applications or large markets,
• A synopsis of more than 100 enzyme inhibitors, including those currently marketed and those in Phase II or later development,
• An overview of the leading indications for available and emerging enzyme inhibitors. These include selected indications for asthma and chronic obstructive pulmonary disease (COPD), cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related inflammatory diseases,
• Forecasts for the global market, through 2011,
• Company Profiles emphasizing companies that lead the pharmaceutical and biotechnology industry in the research and development of enzyme-inhibiting drugs.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.